ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Para descargar el pdf de este artículo: cenm.ag/antivirales.
Referencias usadas para crear esta infografía:
Dance, Amber. “The Challenges of Antiviral Treatments.” Knowable Magazine, Feb. 9, 2021.
De Clercq, Erik. “Antivirals: Past, Present and Future.” Biochem. Pharmacol. (2013). DOI: 10.1016/j.bcp.2012.12.011.
De Clercq, Erik. “Antivirals and Antiviral Strategies.” Nat. Rev. Microbiol. (2004). DOI: 10.1038/nrmicro975.
De Clercq, Erik, and Guangdi Li. “Approved Antiviral Drugs over the Past 50 Years.” Clin. Microbiol. Rev. (2016). DOI: 10.1128/CMR.00102-15.
Dolgin, Elie. “The Race for Antiviral Drugs to Beat COVID—and the Next Pandemic.” Nature, April 14, 2021.
Field, Hugh J., and Erik De Clercq. “Antiviral Drugs–a Short History of Their Discovery and Development.” Microbiology Today, May 1 2004.
Una colaboración entre C&EN y Andy Brunning, autor del blog de los famosos gráficos de Compound Interest (compoundchem.com)
Para ver todas otro articulos de C&EN en español, visita cenm.ag/espanol.
La versión original (en inglés) de este artículo se publicó el Jan. 30, 2022, está disponible aquí.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X